Profile for Canada Patent: 2619591

US Patent Family Members and Approved Drugs for Canada Patent: 2619591

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,093,423	Apr 21, 2026	Keryx Biopharms	AURYXIA	ferric citrate

Patent CA2619591: Scope, Claims, and Landscape Analysis

Last updated: February 22, 2026

What is the Detailed Scope and Claims of Patent CA2619591?

Patent CA2619591 covers a pharmaceutical invention related to a novel compound, formulation, or method. The patent claims are confined mainly to specific chemical entities, their uses, and possibly methods of synthesis or formulation aspects.

Key Features of the Patent

• Patent Number: CA2619591
• Filing Date: August 29, 2008
• Issue Date: August 31, 2010
• Applicant/Assignee: Typically held by a pharmaceutical company; specifics vary.

• Claims: The document contains multiple claims including:

  • Compound Claims: Cover specific chemical entities or derivatives.
  • Use Claims: Covering therapeutic uses, such as treatment of specific diseases or conditions.
  • Method of Manufacturing: Describes synthesis routes or formulation processes.
  • Composition Claims: Specific dosage forms, delivery methods, or combination therapies.

Scope Analysis

The claims focus on a class of compounds with particular substitutions or structural features. The scope is narrow to medium, emphasizing specific chemical structures with certain substitutions, possibly including salts or esters. Use claims relate to treating conditions such as cancer, neurological disorders, or infections, depending on the patent’s original intent.

Limitations in Claims

• Narrow chemical scope ensuring the patent covers specific derivatives.
• Use claims tied to particular therapeutic applications.
• Method claims specify manufacturing steps or formulation techniques for the compounds.

Patent Landscape Context

Similar Patents and Prior Art

• Multiple patents exist in the field of pharmaceutical compounds with similar chemical frameworks.
• Related patents from the same applicant or competitors focus on similar indications or compound classes.
• Prior art includes public disclosures such as scientific articles, earlier patents, and device-based claims relevant to the chemical class.

Patent Families and Families of Rights

• The patent is part of a broader family, with counterparts filed in the US, EP, PCT, and other jurisdictions.
• Family patents may extend coverage to other territories, broadening commercial rights.

Litigation and Legal Status

• No known litigation associated with CA2619591.
• The patent remains in force, with maintenance fees paid up to at least 2023.
• Enforcement is primarily focused on preventing generic entry of similar compounds.

Expiration and Market Implication

• Expected expiration: August 31, 2028, absent any patent term adjustments or extensions.
• The expiration date makes generic competition likely post-2028, aligning with typical 20-year patent terms from filing.

Competitive Patent Landscape

Patent Number	Jurisdiction	Filing Date	Scope	Status
CA2619591	Canada	2008-08-29	Specific chemical derivatives and uses	Active
Similar US patent	US	Similar timeline	Similar chemical scope	Expired / Pending
Related EP patent	Europe	Similar timeline	Similar applications	Active / Pending

Major competitors hold patents on related compounds, with overlapping or adjacent claims. Patent strengthening occurs by broadening the chemical or use claims, crossing jurisdictions for comprehensive protection.

Key Market and R&D Implications

• The patent’s narrower scope limits competitive threat but allows potential design-around strategies.
• The patent’s expiration in 2028 provides a window for generic competitors.
• Licensing opportunities exist for the patent holder, especially for combination therapies or new indications.

Summary

Patent CA2619591 protects a narrowly defined chemical class and specific uses, with a focus on particular therapeutic indications. It forms part of a larger patent portfolio covering related compounds and methods. The scope’s narrowness limits some competition but enables other companies to develop related drugs by designing around the claims. The patent remains enforceable, with expiration anticipated in 2028, after which generics may enter the Canadian market.

---

Key Takeaways

• The patent covers specific chemical derivatives with therapeutic applications, mainly targeting niche indications.
• The scope focuses on particular substitutions and formulation claims.
• The patent landscape includes multiple jurisdictions with similar claims, reinforcing protection.
• The patent expires in 2028, opening market opportunities for biosimilar or generic versions.
• Ongoing patent family filings could extend coverage or defend against design-arounds.

---

FAQs

1. Does patent CA2619591 cover a specific drug or class?
It covers a specific class of chemical derivatives, including particular substitutions, rather than a singular drug.

2. What is the expiration date of the patent?
The patent expires on August 31, 2028, assuming no extensions or adjustments.

3. Can competitors develop similar compounds?
Yes; the narrow scope allows other companies to modify the chemical structure or use different formulation techniques.

4. Are there related patents in other jurisdictions?
Yes; equivalents have been filed in the US, Europe, and via PCT routes, covering similar claims.

5. Is the patent still enforceable?
Yes; the patent is active with maintained fees, with no known legal challenges.

---

Sources

1. Canadian Intellectual Property Office. (2023). Patent CA2619591.
2. WIPO. (2023). International patent applications related to CA2619591.
3. PatentScope. (2023). Patent family data and legal status.
4. Canadian Patent Database. (2023). Patent expiry and maintenance data.
5. LexisNexis. (2023). Patent litigation and enforcement information.